BPG is committed to discovery and dissemination of knowledge
Homepage
Online Submission
Number of total visits
3161112
Number of visits today
2352
Number of downloads
2314641
MEMBERSHIP
Cited by in F6Publishing
Number
Citing Articles
1
Menon D , Urra Pincheira A , Bril V . Emerging drugs for the treatment of myasthenia gravis. Expert Opin Emerg Drugs 2021;26 :259-70. [PMID: 34228579 DOI: 10.1080/14728214.2021.1952982 ] [ Reference Citation Analysis ]
2
Fattizzo B , Serpenti F , Giannotta JA , Barcellini W . Difficult Cases of Paroxysmal Nocturnal Hemoglobinuria: Diagnosis and Therapeutic Novelties. J Clin Med 2021;10 :948. [PMID: 33804461 DOI: 10.3390/jcm10050948 ] [ Cited by in Crossref: 1] [ Cited by in F6Publishing: 1 ] [ Article Influence: 1.0 ] [ Reference Citation Analysis ]
3
Hussein NH , Amin NS , El Tayebi HM . GPI-AP: Unraveling a New Class of Malignancy Mediators and Potential Immunotherapy Targets. Front Oncol 2020;10 :537311. [PMID: 33344222 DOI: 10.3389/fonc.2020.537311 ] [ Reference Citation Analysis ]
4
Lee SE , Lee JW . Safety of current treatments for paroxysmal nocturnal hemoglobinuria. Expert Opin Drug Saf 2021;20 :171-9. [PMID: 33249943 DOI: 10.1080/14740338.2021.1857723 ] [ Cited by in F6Publishing: 2 ] [ Reference Citation Analysis ]
5
Cheng WY , Sarda SP , Mody-Patel N , Krishnan S , Yenikomshian M , Mahendran M , Lejeune D , Yu LH , Duh MS . Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population. Adv Ther 2021;38 :4461-79. [PMID: 34275086 DOI: 10.1007/s12325-021-01825-4 ] [ Cited by in Crossref: 1] [ Article Influence: 1.0 ] [ Reference Citation Analysis ]
© 2004-2022 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA California Corporate Number: 3537345
